TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.2, pp.413-419, 2022 (SCI-Expanded)
Background/aim: Thrombocytopenia is a common complication following hematopoietic stem cell transplantation (HSCT). Eltrombopag has been used in thrombocytopenia treatment after liscr in recent years. Herein, we present our experience of 25 patients treated with eltrombopag for post-HSCT thrombocytopenia.